<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-015-0602-8</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii
               trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled
               trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Kingsbury</span>
               <span tagx="mi">R</span>
               <span tagx="fnm">Sarah</span>
               <span tagx="insr"></span>
               <a href="s.r.kingsbury@leeds.ac.uk">s.r.kingsbury@leeds.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Tharmanathan</span>
               <span tagx="fnm">Puvan</span>
               <span tagx="insr"></span>
               <a href="puvan.nathan@york.ac.uk">puvan.nathan@york.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Arden</span>
               <span tagx="mi">K</span>
               <span tagx="fnm">Nigel</span>
               <span tagx="insr"></span>
               <a href="nigel.arden@ndorms.ox.ac.uk">nigel.arden@ndorms.ox.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Batley</span>
               <span tagx="fnm">Michael</span>
               <span tagx="insr"></span>
               <a href="mbatley@nhs.net">mbatley@nhs.net</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Birrell</span>
               <span tagx="fnm">Fraser</span>
               <span tagx="insr"></span>
               <a href="Fraser.Birrell@newcastle.ac.uk">Fraser.Birrell@newcastle.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Cocks</span>
               <span tagx="fnm">Kim</span>
               <span tagx="insr"></span>
               <a href="kim.cocks@york.ac.uk">kim.cocks@york.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Doherty</span>
               <span tagx="fnm">Michael</span>
               <span tagx="insr"></span>
               <a href="Michael.doherty@nottingham.ac.uk">Michael.doherty@nottingham.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Edwards</span>
               <span tagx="mi">J</span>
               <span tagx="fnm">Chris</span>
               <span tagx="insr"></span>
               <a href="cedwards@soton.ac.uk">cedwards@soton.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Garrood</span>
               <span tagx="fnm">Toby</span>
               <span tagx="insr"></span>
               <a href="toby.garrood@gstt.nhs.uk">toby.garrood@gstt.nhs.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Grainger</span>
               <span tagx="mi">J</span>
               <span tagx="fnm">Andrew</span>
               <span tagx="insr"></span>
               <a href="andrewgrainger@nhs.net">andrewgrainger@nhs.net</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Green</span>
               <span tagx="fnm">Michael</span>
               <span tagx="insr"></span>
               <a href="Michael.Green@york.nhs.uk">Michael.Green@york.nhs.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hewitt</span>
               <span tagx="fnm">Catherine</span>
               <span tagx="insr"></span>
               <a href="catherine.hewitt@york.ac.uk">catherine.hewitt@york.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hughes</span>
               <span tagx="fnm">Rod</span>
               <span tagx="insr"></span>
               <a href="Rod.Hughes@asph.nhs.uk">Rod.Hughes@asph.nhs.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Moots</span>
               <span tagx="fnm">Robert</span>
               <span tagx="insr"></span>
               <a href="R.J.Moots@liverpool.ac.uk">R.J.Moots@liverpool.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">O’Neill</span>
               <span tagx="mi">W</span>
               <span tagx="fnm">Terence</span>
               <span tagx="insr"></span>
               <a href="terence.oneill@manchester.ac.uk">terence.oneill@manchester.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Roddy</span>
               <span tagx="fnm">Edward</span>
               <span tagx="insr"></span>
               <a href="e.roddy@keele.ac.uk">e.roddy@keele.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Scott</span>
               <span tagx="mi">L</span>
               <span tagx="fnm">David</span>
               <span tagx="insr"></span>
               <a href="d.scott1@nhs.net">d.scott1@nhs.net</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Watt</span>
               <span tagx="mi">E</span>
               <span tagx="fnm">Fiona</span>
               <span tagx="insr"></span>
               <a href="fiona.watt@kennedy.ox.ac.uk">fiona.watt@kennedy.ox.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Torgerson</span>
               <span tagx="mi">J</span>
               <span tagx="fnm">David</span>
               <span tagx="insr"></span>
               <a href="david.torgerson@york.ac.uk">david.torgerson@york.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Conaghan</span>
               <span tagx="mi">G</span>
               <span tagx="fnm">Philip</span>
               <span tagx="insr"></span>
               <a href="p.conaghan@leeds.ac.uk">p.conaghan@leeds.ac.uk</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of
                  Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University
                  of Leeds, Chapeltown Road, Leeds LS7 4SA, UK
               </p>
            </li>
            <li tagx="ins">
               <p>York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree
                  Building, University of York, Heslington, York YO10 5DD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics,
                  Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University
                  of Oxford, Windmill Road, Headington, Oxford OX3 7LD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Pembury, Tunbridge
                  Wells TN2 4QJ, Kent, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Musculoskeletal Research Group, Institute for Cellular Medicine, Newcastle University,
                  Musculoskeletal Research Group, 4th Floor Catherine Cookson Building, The Medical
                  School, Framlington Place, Newcastle University, Newcastle NE2 4HH, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Academic Rheumatology, Clinical Sciences Building, University of Nottingham, Nottingham
                  City Hospital, Hucknall Road, Nottingham NG5 1 PB, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Rheumatology and NIHR Wellcome Trust Clinical Research Facility, University
                  Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Guy’s and St Thomas’ Hospitals Foundation NHS Trust, Great Maze Pond, London SE1 9RT,
                  UK
               </p>
            </li>
            <li tagx="ins">
               <p>The York Hospital, York Hospitals NHS Foundation Trust, Wigginton Road, York YO31
                  8HE, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Rheumatology Department, St Peters Hospital, Guildford Road, Chertsey KT16 0PZ, Surrey,
                  UK
               </p>
            </li>
            <li tagx="ins">
               <p>Institute of Integrative Biology, University of Liverpool and Institute of Ageing
                  and Chronic Disease, University Hospital Aintree, Longmoor Lane, Fazakerley, Liverpool
                  L9 7AL, Merseyside, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Arthritis Research UK Centre for Epidemiology, The University of Manchester, 2nd floor,
                  Stopford Building, Oxford Road, Manchester M13 9PT, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Research Institute for Primary Care and Health Sciences, Keele University, Keele ST5
                  5BG, Staffordshire, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Rheumatology, King’s College London School of Medicine, King’s College
                  London and Department of Rheumatology, King’s College Hospital, 10 Cutcombe Road,
                  London SE5 9RJ, London, UK
               </p>
            </li>
            <li tagx="ins">
               <p>Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology
                  and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7HE,
                  UK and Imperial College London, South Kensington Campus, London SW7 2AZ, UK
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">77</span>
         <a href="http://www.trialsjournal.com/content/16/1/77">http://www.trialsjournal.com/content/16/1/77</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-015-0602-8</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">5</span>
               <span tagx="month">11</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">11</span>
               <span tagx="month">2</span>
               <span tagx="year">2015</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">4</span>
               <span tagx="month">3</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Kingsbury et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Double-blind</li>
         <li tagx="kwd">Knee osteoarthritis</li>
         <li tagx="kwd">Methotrexate</li>
         <li tagx="kwd">Placebo-controlled</li>
         <li tagx="kwd">Randomized</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current
                  treatments for OA are severely limited and a large proportion of people with OA live
                  in constant, debilitating pain. There is therefore an urgent need for novel treatments
                  to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In
                  inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold
                  standard treatment for synovitis and has a well-known, acceptable toxicity profile.
                  We propose that using MTX to treat patients with symptomatic knee OA will be a practical
                  and safe treatment to reduce synovitis and, consequently, pain.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III
                  trial of Treatment Effectiveness (PROMOTE) is an investigator-initiated, multi-centre,
                  randomized, double-blind, pragmatic placebo-controlled trial. A total of 160 participants
                  with symptomatic knee OA will be recruited across primary and secondary care sites
                  in the United Kingdom and randomized on a 1:1 basis to active treatment or placebo,
                  in addition to usual care, for 12 months. As is usual practice for MTX, dosing will
                  be escalated over six weeks to 25 mg (or maximum tolerated dose) weekly for the remainder
                  of the study. The primary endpoint is change in average knee pain during the past
                  week (measured on an 11-point numerical rating scale) between baseline and six months.
                  Secondary endpoints include other self-reported pain, function and quality-of-life
                  measures. A health economics analysis will also be performed. A magnetic resonance
                  imaging substudy will be conducted to provide an explanatory mechanism for associated
                  symptom change by examining whether MTX reduces synovitis and whether this is related
                  to symptom change. Linear and logistic regression will be used to compare changes
                  between groups using univariable and multivariable modelling analyses. All analyses
                  will be conducted on an intention-to-treat basis.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>The PROMOTE trial is designed to examine whether MTX is an effective analgesic treatment
                  for OA. The MRI substudy will address the relationship between synovitis and symptom
                  change. This will potentially provide a much needed new treatment for knee OA.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>Current Controlled Trials identifier: 
                  <a href="ISRCTN77854383">ISRCTN77854383</a> (registered: 25 October 2013).
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>With a rapidly ageing population, osteoarthritis (OA) has become the fastest growing
         cause of disability worldwide 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. Current estimates suggest that over 250 million people across the globe are affected
         by OA, with a lifetime risk for the development of knee OA of approximately 40% 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. OA is characterized by chronic joint pain and functional impairment, resulting in
         markedly reduced quality of life for individuals. OA also places an enormous burden
         on health services and health economies, and is the second leading cause of absence
         from work 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>. The cumulative cost of OA has been estimated to amount to approximately 1% of gross
         national product 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>.
      </p>
      <p>One of the major barriers to reducing the impact of OA, both on individuals and society,
         is the lack of efficacious therapies available to treat the symptoms of OA or to slow
         the disease process and associated structural progression. Current management guidelines
         for OA include pharmacological therapies such as paracetamol and NSAIDs, and non-pharmacological
         therapies including weight loss and exercise 
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>. Although current treatments are aimed at providing symptomatic relief, recent studies
         suggest that the large majority of people with OA live in constant pain despite use
         of available therapies 
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. These therapies are also associated with significant toxicities. In addition, because
         the typical OA patient is of advanced age with multiple comorbidities, many have contraindications
         to the use of traditional OA medications. Hence, there is a pressing need to identify
         alternative therapies for OA in order to tackle this increasing problem 
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>.
      </p>
      <p>There is increasing evidence, particularly from imaging studies, of a high prevalence
         of synovitis (inflammation of the synovial membrane) in OA, with abnormalities present
         from the earliest stages of the disease and associated with the presence and severity
         of pain 
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">18</span>
         </span>. These changes are often indistinguishable to those observed in rheumatoid arthritis
         (RA), although they are generally confined to more discrete regions within the joint,
         generally adjacent to sites of chondropathy. Increased levels of pro-inflammatory
         cytokines (such as tumour necrosis factor (TNF)α, interleukin (IL)-1β and IL-6), reduced
         levels of anti-inflammatory cytokines (such as IL-10 and IL-1RA), infiltration of
         mononuclear cells and adaptive immune cell responses have all been demonstrated within
         OA fluid and tissue, suggesting that modulating the inflammatory response may be effective
         as a treatment target for OA 
         <span tagx="abbrgrp">
            <span tagx="abbr">19</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">21</span>
         </span>.
      </p>
      <p>The rationale for targeting synovitis as a treatment for OA pain is supported by previous
         studies of anti-inflammatory agents. Randomized controlled trials of non-steroidal
         anti-inflammatory drugs (NSAIDs) and the fewer randomized controlled trials of intra-articular
         (IA) and oral corticosteroids have demonstrated modest, short-term pain reduction
         associated with anti-inflammatory effects and reduced synovitis 
         <span tagx="abbrgrp">
            <span tagx="abbr">22</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">27</span>
         </span>. However, although NSAIDs and corticosteroids have positive short-term effects their
         long-term use is not desirable, with contra-indications to their use in many people
         with OA.
      </p>
      <p>Disease modifying anti-rheumatic drugs (DMARDs) are the mainstay of treatment for
         RA and all have anti-synovial effects. Methotrexate ((MTX) 4-amino-10-methylfolic
         acid) is the first-line treatment widely used to treat synovitis in the inflammatory
         arthritides, and current evidence suggests it is the most effective DMARD and safe
         for long-term use 
         <span tagx="abbrgrp">
            <span tagx="abbr">28</span>
         </span>. Indications for the use of MTX have expanded in recent years to include trials to
         reduce cardiovascular disease (CVD) in the general population, as well as showing
         reductions in CVD in RA patients 
         <span tagx="abbrgrp">
            <span tagx="abbr">29</span>
         </span>. There is more uncertainty about the benefits of MTX in other peripheral joint arthritides
         such as psoriatic arthritis (PsA), however this may reflect a lack of robust trial
         data 
         <span tagx="abbrgrp">
            <span tagx="abbr">30</span>
         </span>.
      </p>
      <p>MTX is a folic acid antagonist which has both an anti-proliferative and an anti-inflammatory
         action. The anti-proliferative activity of MTX is mediated through inhibition of the
         
         <i>de novo</i> synthesis of purines and pyrimidines by acting as a specific antagonist of folic
         acid. MTX was initially used in high doses for its anti-proliferative effect in the
         treatment of cancer, at doses of up to 5,000 mg per week. At much lower doses (15
         to 25 mg per week), as used in inflammatory arthritis, MTX has an anti-inflammatory
         effect by inducing an increase in adenosine release from cells through selective inhibition
         of aminoimidazole carboxamide ribonucleotide (AICAR) transformylase, an enzyme that
         catalyses an intermediary step in 
         <i>de novo</i> purine biosynthesis. Extracellular adenosine is a potent inhibitor of inflammation,
         suppressing the inflammatory functions of neutrophils, macrophages and monocytes,
         dendritic cells and lymphocytes, thereby reducing secretion of inflammatory cytokines,
         including TNFα and IL-6, which drive synovitis 
         <span tagx="abbrgrp">
            <span tagx="abbr">31</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">32</span>
         </span>.
      </p>
      <p>Given the high levels of pro-inflammatory cytokines and the evidence of immune cell
         infiltration into OA joints, coupled with the strong correlations observed between
         synovitis and pain, there is rationale for the use of MTX for reducing symptoms in
         OA. Most patients tolerate MTX for long-term use 
         <span tagx="abbrgrp">
            <span tagx="abbr">33</span>
         </span> and the use of folic acid concomitantly with MTX reduces the incidence of side-effects
         
         <span tagx="abbrgrp">
            <span tagx="abbr">34</span>
         </span>. Patients undergo regular blood monitoring to assess for toxicity, and abnormalities
         in results usually respond to a dose reduction or temporary cessation, or an increase
         in folic acid supplementation. Side-effects of MTX can include gastrointestinal side-effects,
         haematological abnormalities and elevated liver transaminases. Side-effects resulting
         in discontinuation of the drug vary in frequency from 15 to 17% 
         <span tagx="abbrgrp">
            <span tagx="abbr">35</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">36</span>
         </span>, but have been shown to reduce to 4% in the second year of treatment 
         <span tagx="abbrgrp">
            <span tagx="abbr">35</span>
         </span>.
      </p>
      <p>To date there have been no large trials of MTX for treating OA. Two small studies,
         one in knee OA and the other in hand OA, have been carried out and these had conflicting
         results (Figure 
         <div tagx="figr">1</div> and Table 
         <span tagx="tblr">1</span>) 
         <span tagx="abbrgrp">
            <span tagx="abbr">37</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">38</span>
         </span>. One additional study examined the effect of MTX in calcium pyrophosphate crystal
         disease (CPPD) 
         <span tagx="abbrgrp">
            <span tagx="abbr">39</span>
         </span>. However, these studies included very low patient numbers and small doses of MTX,
         which makes it difficult to determine whether the results are valid.
         
         
      </p>
      <div tagx="fig">
         <div tagx="title">
            <p>Figure 1</p>
         </div>
         <caption>
            <p>Overview of systematic review of methotrexate use in osteoarthritis. </p>
         </caption>
         <div tagx="text">
            <p>
               <b>Overview of systematic review of methotrexate use in osteoarthritis.</b> Databases: PubMed, MEDLINE and Embase. Search terms: MeSH headings #1 ‘osteoarthritis’
               and #2 ‘methotrexate’. Limits: Humans.
            </p>
         </div>
         <div tagx="graphic"></div>
      </div>
      <table>
         <div tagx="title">
            <p>Table 1</p>
         </div>
         <caption>
            <p>
               <b>Systematic review of methotrexate use in osteoarthritis</b>
            </p>
         </caption>
         <tgroup>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <thead>
               <tr>
                  <td>
                     <p>
                        <b>Reference</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>n</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Site</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Treatment</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Outcome</b>
                     </p>
                  </td>
               </tr>
            </thead>
            <div tagx="tfoot">
               <p>CPPD, calcium pyrophosphate deposition disease; MTX, methotrexate; OA, osteoarthritis;
                  VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Osteoarthritis Index.
               </p>
            </div>
            <tbody>
               <tr>
                  <td>
                     <p>de Holanda 2007 
                        <span tagx="abbrgrp">
                           <span tagx="abbr">37</span>
                        </span>
                     </p>
                  </td>
                  <td>
                     <p>58</p>
                  </td>
                  <td>
                     <p>Knee OA</p>
                  </td>
                  <td>
                     <p>Double-blind, placebo controlled, 4 months, 7.5 mg/week</p>
                  </td>
                  <td>
                     <p>No statistically significant difference between both groups regarding WOMAC (
                        <i>P</i> = 0.94), Lequèsne Algofunctional Index (
                        <i>P</i> = 0.87) and VAS (
                        <i>P</i> = 0.89. No significant difference in paracetamol consumption between both groups,
                        however, there was tendency to increased consumption in the placebo group.
                     </p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Pavelka 2006 
                        <span tagx="abbrgrp">
                           <span tagx="abbr">38</span>
                        </span>
                     </p>
                  </td>
                  <td>
                     <p>21</p>
                  </td>
                  <td>
                     <p>Erosive hand OA</p>
                  </td>
                  <td>
                     <p>Open label, 10 mg of MTX orally for two months</p>
                  </td>
                  <td>
                     <p>Significant decrease of pain after 2 months of treatment (54.4 ± 17.0 mm versus 39.7 ± 19.6 mm,
                        
                        <i>P</i> &lt;0.01) and stiffness (28.8 ± 24 min versus 21.8 ± 19.1 min, 
                        <i>P</i> &lt;0.01)
                     </p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Chollet-Janin 2007 
                        <span tagx="abbrgrp">
                           <span tagx="abbr">39</span>
                        </span>
                     </p>
                  </td>
                  <td>
                     <p>5</p>
                  </td>
                  <td>
                     <p>CPPD</p>
                  </td>
                  <td>
                     <p>Open label, 5 to 20 mg/week</p>
                  </td>
                  <td>
                     <p>Clinical response in all 5 patients with significant reduction in pain intensity,
                        swollen and tender joint counts and mean improvement time of 7.4 weeks
                     </p>
                  </td>
               </tr>
            </tbody>
         </tgroup>
      </table>
      <p>More recently, we conducted an open-label pilot study of 30 patients with knee OA
         who took MTX for six months 
         <span tagx="abbrgrp">
            <span tagx="abbr">40</span>
         </span>. A total of 23 patients completed the study, 20 of whom were taking a MTX dose of
         15 mg/week or more. At six months, 50% of patients had a 20% reduction in pain, whilst
         37% had a 40% reduction in pain. Of the seven participants who did not complete the
         study, four withdrew due to side effects (lethargy, nausea and headaches in three
         patients and thrush in one patient) and three withdrew due to lack of response. Further
         evidence for the potential of MTX as a therapy for OA can be extrapolated from animal
         studies, with positive effects on cartilage demonstrated in lapine models of OA 
         <span tagx="abbrgrp">
            <span tagx="abbr">41</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">42</span>
         </span>.
      </p>
      <p>Taken together these clinical and experimental studies suggest potential for MTX as
         a useful treatment for OA. We propose that treating patients with symptomatic knee
         OA with MTX will be a practical and safe treatment to reduce synovitis and therefore
         reduce pain. We believe that the preliminary data from the handful of small studies
         previously conducted, including our pilot study, strongly support the need for a well-designed,
         adequately powered, randomized placebo-controlled trial to examine fully the potential
         use of MTX as a treatment for OA. The Pain Reduction with Oral Methotrexate in knee
         Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness (PROMOTE) was
         designed to this end.
      </p>
      <p>This paper states the objective of the PROMOTE trial, discusses study design challenges
         encountered in its planning, and outlines the resultant study design and protocol
         for the PROMOTE trial.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Trial objectives</h3>
         </div>
         <p>The primary objective of the trial is to determine whether MTX reduces pain associated
            with knee OA as compared to placebo. Secondary objectives of the trial are:
         </p>
         <p>1. To determine whether MTX improves function,</p>
         <p>2. To determine whether MTX improves quality of life and</p>
         <p>3. To determine whether MTX is a cost-effective treatment for knee OA.</p>
         <p>In addition to the main study, PROMOTE contains a magnetic resonance imaging (MRI)
            substudy and a biological substudy. Patients enrolled in the main study may opt to
            enrol in one, both or neither of the sub-studies. The objective of the MRI substudy
            is to provide an explanatory mechanism for associated symptom change by examining
            whether MTX reduces synovitis, and whether this is related to symptom change. The
            objective of the biological substudy is to determine whether baseline soluble immunological
            and inflammatory biomarkers predict response to treatment, and whether changes in
            levels occur following treatment with MTX.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Trial development</h3>
         </div>
         <p>The trial was designed with key stakeholders including rheumatologists with experience
            of treating OA, general practitioners with a special interest in musculoskeletal disease,
            methodologists and users with experience of knee OA. The intention was to be pragmatic,
            allowing physicians to include MTX in the overall care of patients with knee OA and
            have relative flexibility in this regard, thereby being representative of clinical
            practice. We faced a number of challenges in achieving the ideal design for the PROMOTE
            trial which are discussed in more detail in the relevant sections below. Key challenges
            included defining the dosing and dose escalation strategy for use of MTX in OA patients,
            maintaining the blind due to the well-known side-effect profile of MTX, timing of
            the primary outcome, ensuring optimal recruitment for a trial that is conducted in
            secondary care for a condition where patients predominantly reside in primary care
            and maintaining the pragmatic nature of the trial with respect to concomitant medication
            use, whilst protecting the validity of the primary pain outcome.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/Design</h2>
      </div>
      <p>The PROMOTE trial is an investigator-initiated, multi-centre, 160 patient, randomized
         placebo-controlled trial to compare the reduction in pain associated with knee OA
         with MTX as compared to placebo. Participants will be randomized on a 1:1 basis to
         MTX or placebo, and treatment will be for 12 months.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Population</h3>
         </div>
         <p>All adults with symptomatic radiographic knee OA and inadequate response or toxicity
            to their existing medication (to include paracetamol, NSAIDs or opioid).
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Intervention and comparator</h3>
         </div>
         <p>Participants will be randomized to receive either over-encapsulated MTX 2.5 mg tablets
            (packed with microcrystalline cellulose (Sharp Clinical Services (UK) Ltd, Crickhowell,
            Wales)) or placebo (matching capsules packed with microcrystalline cellulose (Sharp
            Clinical Services (UK) Ltd, Crickhowell, Wales)).
         </p>
         <div id="">
            <div tagx="st">
               <h4>Choice of dosing for methotrexate in patients with osteoarthritis</h4>
            </div>
            <p>MTX is currently used in RA with a maximum dose of 25 mg per week. Previous small
               studies in OA have used lower doses than those used in RA 
               <span tagx="abbrgrp">
                  <span tagx="abbr">37</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">38</span>
               </span>; however to alleviate concerns around inefficacy due to inadequate dosing, we will
               follow current guidelines for use of MTX in RA as the model for the PROMOTE trial.
               Participants will be prescribed 10 mg MTX or placebo weekly for two weeks, followed
               by 15 mg weekly for two weeks, 20 mg weekly for two weeks and 25 mg weekly for the
               remainder of the study if there is no toxicity as determined at the physician’s discretion
               
               <span tagx="abbrgrp">
                  <span tagx="abbr">43</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">44</span>
               </span>. In practice, slower dose escalation may be necessary in some participants, and deviations
               from this protocol (for example escalation by 2.5 mg every two weeks) will be permitted
               at the clinician’s discretion to bring participants to the maximum tolerated dose
               as closely in line with the stated strategy as possible.
            </p>
            <p>If participants show toxicity to MTX upon dose escalation the dose will be dropped
               to the maximum tolerated dose (minimum dose, 7.5 mg/week) and this will be maintained
               for the duration of the study. In our pilot study of MTX in OA, 20 of the 23 participants
               completing the study did so on a dose of 15 mg or more. Dose reduction (to 7.5 to
               12.5 mg) was required in four participants; one due to renal impairment and three
               due to side effects (nausea, headache and sore roof of mouth), all of which improved
               upon dose reduction. Participants who are intolerant of oral MTX will not be switched
               to subcutaneous MTX (a common practice for RA), due to complexities in maintaining
               the blind.
            </p>
            <p>All participants will be routinely reminded and encouraged to comply with the prescribed
               dose of investigational medicinal product (IMP). However, given the long half-life
               of MTX, those who miss doses of IMP will be allowed to restart medication if they
               so wish, and will not be handled differently during the course of follow-up. For the
               purposes of analysis, a participant missing more than four doses of MTX within any
               three-month period will be counted as a ‘non-complier’.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Non-investigational medicinal product</h4>
            </div>
            <p>All participants will be prescribed oral folic acid 5 mg tablets to be taken on the
               six consecutive days after taking the weekly MTX or placebo dose. Folic acid supplementation
               has been shown to ameliorate side effects associated with MTX’s activity as an antagonist
               of folic acid metabolism 
               <span tagx="abbrgrp">
                  <span tagx="abbr">45</span>
               </span>.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Concomitant medication</h4>
            </div>
            <p>In order to maintain the pragmatic nature of the trial, there are no restrictions
               written into the protocol with regard to concomitant analgesic medications. All participants,
               whether on MTX or placebo, will be allowed to continue taking the treatments for knee
               OA that they are taking at their screening visit for the duration of the trial. Investigators
               will be responsible for the overall management of a participant’s medication, and
               will ask participants to avoid changing their analgesic or anti-inflammatory medication
               for the duration of the trial. However, if a participant is experiencing increased
               pain and requires an increase in the dose of analgesics then the use of paracetamol,
               topical or oral NSAIDs or opioids, or a combination of these will be permitted, but
               the reason for the dose increase and the dose used will be documented. The choice
               of medications and doses to be used lie with the principal investigator and clinicians
               working at study sites in order to ensure that treatment for participants in both
               groups is optimized. Participants will be permitted to continue current use of chondroitin
               and glucosamine, provided the dose has been stable for three months at study entry;
               however their use must be clearly documented in the case report form (CRFChondroitin
               or glucosamine therapy will not be commenced during the duration of the trial. Chronic
               NSAID and opioid use days in the last three months) will be included as a covariate
               in the analysis.
            </p>
            <p>The exception to this rule is corticosteroid use, since corticosteroids may have a
               significant effect on a participant’s experience of pain, to the point of affecting
               response to the primary outcome. Whilst there will be no overall restriction on the
               use of corticosteroids, the protocol provides guidance to investigators on the use
               of corticosteroids in order to minimise effects on the primary outcome, as detailed
               below. Participants will be asked not to use corticosteroids (oral, intravenous, IA
               or intra-muscular) between months three to six of the trial (three months before the
               primary endpoint). In months zero to three and six to 12 a single IA corticosteroid
               (in a non-knee joint) and up to one week of oral corticosteroids will be permitted.
               If corticosteroids are deemed necessary for medical reasons then their date of use,
               dose, route and indication must be clearly documented in the CRF. Patients will be
               offered the option of a rescue IA corticosteroid injection to their signal knee after
               the six-month visit of the trial if their symptoms are intolerable despite current
               medication. Corticosteroid use is ultimately at the discretion of the principal investigatoror
               study physician. All steroid use must be notified to the PROMOTE trial team centrally,
               but this will not affect the participant’s continued follow-up in the trial.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Outcome measures</h3>
         </div>
         <p>The PROMOTE trial will examine a range of clinical, imaging and quality-of-life and
            economic outcomes, in line with the objectives listed.
         </p>
         <div id="">
            <div tagx="st">
               <h4>Clinical outcome measures</h4>
            </div>
            <p>The primary endpoint of the study will be change in ‘average overall knee pain severity
               over the previous week’ (as graded on a zero to 10 numerical rating scale (NRS)) between
               baseline and six months (24 weeks). An NRS was chosen to measure pain as they have
               been found to be reliable and to demonstrate good face and criterion validity, and
               they are recommended as a core outcome measure for chronic pain clinical trials by
               the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
               
               <span tagx="abbrgrp">
                  <span tagx="abbr">46</span>
               </span>-
               <span tagx="abbrgrp">
                  <span tagx="abbr">50</span>
               </span>.
            </p>
            <p>The timing of the primary outcome at six months was defined due to the slow-acting
               nature of MTX. Studies in RA have found that several months of treatment may be required
               before any symptomatic effect is noted 
               <span tagx="abbrgrp">
                  <span tagx="abbr">43</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">44</span>
               </span>. Our own recent study of MTX versus MTX plus etanercept in RA, in which the MTX arm
               used the same dosing schedule as that planned for the PROMOTE trial, found that approximately
               20% of participants in the MTX arm showed a major clinically significant response
               (tender and swollen joint count of zero) at three months, with this rising to 29%
               at six months and 33% at 12 months. In our pilot study of MTX in OA, the reduction
               in 48-hour pain VAS scores was significantly greater at 24 weeks (median (interquartile
               range (IQR)) reduction of 27 mm (four to 38)) than at 12 weeks (median (IQR) reduction
               of 9 mm (−1 to 36)).The dose escalation schedule for the PROMOTE trial requires a
               minimum of six weeks to reach maximum dosage, and in reality we know that it can often
               take longer than this to escalate the dosage. Taken together with evidence from the
               RA literature, which suggests that at least two to three months may be required at
               maximal dose for symptomatic benefit to be achieved, a primary outcome earlier than
               six months may fail to fully capture the clinical response to treatment. However,
               additional outcomes will be recorded at three months (12 weeks) to identify early
               response, and nine and 12 months (36 and 48 weeks) to capture longevity of response.
            </p>
            <p>Secondary outcome measures include self-reported assessment of pain and function using
               11-point NRSs to assess worst knee pain severity, global disease activity and satisfaction
               with knee function over the past week, together with the pain, function and stiffness
               subscales of the Western Ontario McMaster Universities Index (WOMAC version 3.1) and
               the Intermittent and Constant Osteoarthritis Pain scale (ICOAP). Depression and anxiety
               will be assessed using the Hospital Anxiety and Depression Scale (HADS). These measures
               are outlined further in Table 
               <span tagx="tblr">2</span>.
               
            </p>
            <table>
               <div tagx="title">
                  <p>Table 2</p>
               </div>
               <caption>
                  <p>
                     <b>Outcome measures</b>
                  </p>
               </caption>
               <tgroup>
                  <colspec></colspec>
                  <colspec></colspec>
                  <colspec></colspec>
                  <colspec></colspec>
                  <colspec></colspec>
                  <colspec></colspec>
                  <thead>
                     <tr>
                        <td></td>
                        <td>
                           <p>
                              <b>Month(s)</b>
                           </p>
                        </td>
                     </tr>
                  </thead>
                  <div tagx="tfoot">
                     <p>
                        <sup>a</sup>A six-point Likert scale: completely better, much better, better, no change, worse
                        or much worse. 
                        <sup>b</sup>Also recorded at 1 and 2 months. HADS, Hospital Anxiety and Depression Scale; ICOAP,
                        Intermittent and Constant Osteoarthritis Pain; NRS, numerical rating scale; OAQoL,
                        Osteoarthritis Quality of Life Scale; VAS, visual analogue scale; WOMAC, Western Ontario
                        McMaster Universities Index.
                     </p>
                  </div>
                  <tbody>
                     <tr>
                        <td></td>
                        <td>
                           <p>
                              <b>0</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>3</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>6</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>9</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>12</b>
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Primary outcome</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Average overall knee pain severity over the previous week (0 to 10 NRS)</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Secondary outcomes</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Imaging assessments:</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>MRI of signal knee</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Clinical assessments:</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Knee examination</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Self-reported questionnaires:</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>WOMAC 3.1 (pain, stiffness and function) - five-point Likert scale</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>ICOAP</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>11-point NRS for:</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Worst knee pain severity,/ global disease activity and pain in other joints over the
                              past week
                           </p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Satisfaction with knee function over the past 2 days</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Knee pain, aching or stiffness over the past month (no days to all days)</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Global
                              <sup>a</sup> improvement in knee problem, pain and function
                           </p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Pain elsewhere (pain manikin)</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Duration of knee pain over the past 12 months (&lt;7 days, 1 to 4 weeks, &gt;1 month, &lt;3 months
                              or &gt;3 months)
                           </p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Onset of knee pain (last 12 months, 1 to 5 years, 5 to 10 years or 10 years or more)</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Quality of life: SF-12 v2 and OAQoL 
                              <span tagx="abbrgrp">
                                 <span tagx="abbr">40</span>
                              </span>
                           </p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>EuroQol EQ-5D 
                              <span tagx="abbrgrp">
                                 <span tagx="abbr">41</span>
                              </span>,
                              <span tagx="abbrgrp">
                                 <span tagx="abbr">42</span>
                              </span>
                           </p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Depression and anxiety: HADS</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Resource use:</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Demographics and medical history</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                     </tr>
                     <tr>
                        <td>
                           <p>Brief medication questionnaire</p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Concomitant medication
                              <sup>b</sup>
                           </p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Adverse events
                              <sup>b</sup>
                           </p>
                        </td>
                        <td></td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                        <td>
                           <p>✓</p>
                        </td>
                     </tr>
                  </tbody>
               </tgroup>
            </table>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Quality-of-life and health economic outcome measures</h4>
            </div>
            <p>Utility will be measured using the EuroQol (EQ-5D-5 L), deriving quality-adjusted
               life years (QALYs) for each participant. Disease-specific quality-of-life measures
               are listed in Table 
               <span tagx="tblr">2</span>.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Imaging outcome measures</h4>
            </div>
            <p>Gadolinium-enhanced 1.5/3.0 T MRI of the signal knee will be performed at baseline
               and six months according to the protocol outlined in Table 
               <span tagx="tblr">3</span>. All images will be quality controlled by an experienced musculoskeletal radiologist
               within two weeks of acquisition to ensure that the image quality is sufficient for
               scoring purposes. MRIs will be centrally scored semi-quantitatively and quantitatively
               at the end of the study. Semi-quantitative scoring will be conducted using the MRI
               Osteoarthritis Knee Score (MOAKS) 
               <span tagx="abbrgrp">
                  <span tagx="abbr">51</span>
               </span>. Images will be quantitatively scored using statistical shape modelling technology
               to automatically quantitate total and compartmental synovial volume, total and compartmental
               bone shape and other relevant features including cartilage morphology 
               <span tagx="abbrgrp">
                  <span tagx="abbr">52</span>
               </span>.
               
            </p>
            <table>
               <div tagx="title">
                  <p>Table 3</p>
               </div>
               <caption>
                  <p>
                     <b>Magnetic resonance imaging acquisition protocol</b>
                  </p>
               </caption>
               <tgroup>
                  <colspec></colspec>
                  <colspec></colspec>
                  <colspec></colspec>
                  <thead>
                     <tr>
                        <td>
                           <p>
                              <b>Plane</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>Sequence</b>
                           </p>
                        </td>
                        <td>
                           <p>
                              <b>Slice Thickness</b>
                           </p>
                        </td>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>
                           <p>Sagittal</p>
                        </td>
                        <td>
                           <p>T1 SE</p>
                        </td>
                        <td>
                           <p>2 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Sagittal</p>
                        </td>
                        <td>
                           <p>PD FSE TE = 40 Fat Saturated</p>
                        </td>
                        <td>
                           <p>3 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Sagittal</p>
                        </td>
                        <td>
                           <p>T2 FSE Fat Saturated</p>
                        </td>
                        <td>
                           <p>3 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Coronal</p>
                        </td>
                        <td>
                           <p>PD FSE TE = 40 Fat Saturated</p>
                        </td>
                        <td>
                           <p>3 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Coronal</p>
                        </td>
                        <td>
                           <p>STIR</p>
                        </td>
                        <td>
                           <p>4 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Axial</p>
                        </td>
                        <td>
                           <p>PD FSE TE = 40 Fat Saturated</p>
                        </td>
                        <td>
                           <p>3 mm</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Post gadolinium:</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Sagittal</p>
                        </td>
                        <td>
                           <p>T1 3D SPGR Fat Saturated/Water Excitation</p>
                        </td>
                        <td>
                           <p>Isotropic</p>
                        </td>
                     </tr>
                  </tbody>
               </tgroup>
            </table>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Sample size</h3>
         </div>
         <p>The standard deviation used in the sample size calculation is an estimate from previous
            studies. The internal pilot study will be used to re-estimate the sample size required
            and increase the recruitment target if necessary.
         </p>
         <p>A data-driven analysis which related change on an NRS with patient global assessment
            of change using data from 10 similar trials of chronic pain showed that a 30% change,
            or two points on the NRS was related to change of clinical importance in chronic pain.
            The correlation between clinician and patient global assessment of change was high
            in this review, and the large sample size used underscores the external validity of
            these estimates 
            <span tagx="abbrgrp">
               <span tagx="abbr">53</span>
            </span>. This estimate of a two-point change on a NRS being associated with a ‘much better’
            improvement was also seen in a prospective cohort of patients with chronic musculoskeletal
            pain 
            <span tagx="abbrgrp">
               <span tagx="abbr">54</span>
            </span>.
         </p>
         <p>In a recent placebo-controlled, 121 patient, OA knee trial using an 11-point pain
            NRS as the primary outcome, the mean (standard deviation (SD)) baseline pain score
            was 6.1 (2.1) in the control group, 7.7 (1.4) in the placebo group, 7.1 (2.8) in treatment
            group A and 6.7 (2.5) in treatment group B 
            <span tagx="abbrgrp">
               <span tagx="abbr">55</span>
            </span>. In a separate 73 patient OA knee trial, the mean (SD) baseline pain score was 4.0
            (2.1) in group A and 4.3 (1.9) in group B. At 12 months, the mean (SD) within-group
            difference was 0.9 (2.1) for group A and 1.3 (2.4) for group B 
            <span tagx="abbrgrp">
               <span tagx="abbr">56</span>
            </span>. For the sample size calculation an SD of 4 is used as a conservative estimate.
         </p>
         <p>The expected consistency in baseline pain among our trial population allows the use
            of raw change in score, rather than percentage change 
            <span tagx="abbrgrp">
               <span tagx="abbr">53</span>
            </span>. In order to detect a two-point change, with an assumed SD of 4 (80% power and 5%
            significance level), 64 participants per arm are required. Allowing for a conservative
            20% dropout rate, a total of 160 participants will therefore need to be recruited
            into the study.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Trial procedures</h3>
         </div>
         <p>Ethical approval for the study has been granted by the Leeds West Research Ethics
            Committee (reference number 13/YH/0279). Informed written consent will be obtained
            from all participants.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Participant recruitment strategy</h3>
         </div>
         <p>Since knee OA is primarily managed within primary care, our recruitment strategy must
            enable a clear interface between primary care centres and the secondary care sites
            at which trial activity will take place. Relevant Clinical Commissioning Group (CCG)
            approvals will be obtained to enable primary care sites to act as Patient Identification
            Centres (PICs), with potentially eligible patients referred on to local secondary
            care study teams.
         </p>
         <p>A total of 160 subjects with symptomatic knee OA will be recruited and randomly allocated
            to either the treatment or placebo control group. Recruitment methods will include
            advertisements through the local media and community groups, invitations to previous
            study participants who have given their consent to be contacted regarding future research
            projects and liaisons with musculoskeletal physicians, general practitioners and allied
            health professionals. Recruitment will be initiated at all sites as soon as local
            approvals are in place, therefore recruitment to the pilot phase may occur from multiple
            sites. There will be no pause in recruitment once 30 patients are recruited, as the
            outcome from the analysis of the pilot phase will be to either continue to the planned
            numbers or to increase the planned sample size.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Informed consent and participant confidentiality</h3>
         </div>
         <p>Informed consent will be obtained before patients are screened for participation in
            the PROMOTE trial. The right of the patient to refuse consent without giving reasons
            will be respected. Further, the patient will remain free to withdraw from the study
            at any time without giving reasons and without prejudicing any further treatment.
            The written consent will be obtained by an appropriately delegated clinician who is,
            by education and experience, qualified to do so, and who has signed and dated the
            staff authorization and delegation log. The process of obtaining written consent will
            be clearly documented in the patient’s medical notes. Patient confidentiality will
            be guaranteed at all times, in line with the requirements of the United Kingdom Data
            Protection Act 1998 and NHS regulations.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Eligibility criteria</h3>
         </div>
         <p>Participants must meet the inclusion and exclusion criteria (shown in Table 
            <span tagx="tblr">4</span>) in order to participate. These will be assessed at the screening visit (Figure 
            <div tagx="figr">2</div>). Potential participants who are deemed ineligible at screening will be allowed a
            second screening visit if the reason for ineligibility is a temporary status (for
            example, recent corticosteroid injection; Table 
            <span tagx="tblr">4</span>).
            
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 4</p>
            </div>
            <caption>
               <p>
                  <b>Eligibility criteria</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Inclusion criteria</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Exclusion criteria</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <div tagx="tfoot">
                  <p>
                     <sup>a</sup>Criteria for which participants may be rescreened if they are ineligible at the initial
                     screening visit. ALT, alanine aminotransferase; COPD, chronic obstructive pulmonary
                     disease; eGFR, estimated glomerular filtration rate; IA, intra-articular; IM, intramuscular;
                     IV, intravenous; RA, rheumatoid arthritis; ULN, upper limit of normal; VAS, visual
                     analogue scale; WCC, white cell count.
                  </p>
               </div>
               <tbody>
                  <tr>
                     <td>
                        <p>Fulfil clinical ACR Criteria for knee OA</p>
                     </td>
                     <td>
                        <p>The presence of any inflammatory arthritis (such as gout, reactive arthritis, rheumatoid
                           arthritis, psoriatic arthritis, seronegative spondyloarthropathy, previous diagnosis
                           of pseudogout in target joint with proven crystals on joint aspiration or elevated
                           CRP at time of knee arthritis flare) or fibromyalgia.
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Knee pain on most days in the last 3 months</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Knee pain is the predominant pain condition</p>
                     </td>
                     <td>
                        <p>Use of intra-articular (IA) hyaluronic acid in the signal knee within the 4 months
                           preceding enrolment in the study
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Insufficient pain relief from, inability to tolerate or contra-indication to oral
                           and/or topical NSAIDs and/or opioids. Moderate to severe pain of the signal knee as
                           defined by a score of ≥40 mm on a VAS (0 to 100 mm) using the question ‘On average,
                           how would you rate your knee pain during the last 3 months?’.
                        </p>
                     </td>
                     <td>
                        <p>Use of IA, IM (intra-muscular) or oral corticosteroids in the 3 months preceding enrolment
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Use of other anti-synovial agents (such as hydroxychloroquine or sulphasalazine) in
                           the 2 months preceding the study
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Significant knee injury or any knee surgery within the 6 months preceding enrolment
                           in the study
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Patient able to identify a ‘signal’ painful knee (either the most painful knee or
                           selected from equally painful knees)
                        </p>
                     </td>
                     <td>
                        <p>The presence of non-OA causes of pain in the signal knee, such as referred hip pain,
                           osteonecrosis or radicular spinal pain
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>A previous radiograph (X-ray) of the signal knee within the last 2 years with changes
                           consistent with tibiofemoral OA
                        </p>
                     </td>
                     <td>
                        <p>Commencement of physiotherapy or non-pharmacological knee OA treatment in the 2 months
                           preceding the study
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>No change in the average weekly dose of oral or topical analgesics (including NSAIDs)
                           for at least 4 weeks
                           <sup>a</sup>
                        </p>
                     </td>
                     <td>
                        <p>A history of partial or complete joint replacement surgery in the signal knee at any
                           time, listed for knee surgery or anticipating knee surgery during the study period
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Has used chondroitin or glucosamine for at least 3 months with no change to the average
                           weekly dose, is not using or is willing to stop using if recently started
                           <sup>a</sup>
                        </p>
                     </td>
                     <td>
                        <p>Women who are pregnant, breast-feeding or men or women planning pregnancy within 18 months
                           after screening (approximately 6 months following last study medications)
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>All male and female subjects biologically capable of having children must agree to
                           use a reliable method of contraception for the duration of the study and 24 weeks
                           after the end of the study period. Acceptable methods of contraception are surgical
                           sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices
                           or barrier contraceptives.
                        </p>
                     </td>
                     <td>
                        <p>Use of any investigational (unlicensed) drug within 1 month prior to screening or
                           within 5 half-lives of the investigational agent, whichever is longer
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
                           haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral
                           disease
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>If female have potential for child bearing then a negative pregnancy test must be
                           performed prior to starting treatment.
                        </p>
                     </td>
                     <td>
                        <p>Poor tolerability of venepuncture or lack of adequate venous access for required blood
                           sampling during the study period
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>The patient must be able to adhere to the study visit schedule and other protocol
                           requirements
                        </p>
                     </td>
                     <td>
                        <p>Uncontrolled disease states, such as moderate or severe asthma, COPD or inflammatory
                           bowel disease, where flares are commonly treated with oral or parenteral corticosteroids,
                           or recurrent infections
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>The patient must be capable of giving informed consent and the consent must be obtained
                           prior to any screening procedures
                        </p>
                     </td>
                     <td>
                        <p>Unwilling to keep alcohol intake to below the recommended maximum daily limit during
                           the trial (2 units per day for women, 3 units per day for men)
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>All patients must have had a chest radiograph (X-ray) within the last 6 months</p>
                     </td>
                     <td>
                        <p>Planned need for live vaccination during 12 months of study (for example for foreign
                           travel) with exception of Zostavax®, which is permissible
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Aged ≥18 years</p>
                     </td>
                     <td>
                        <p>Melanoma or non-skin cancer in the past 3 years
                           <sup>a</sup>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Intolerance to lactose</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Significant haematological or biochemical abnormality:</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Haemoglobin ≤8.5 g/dL</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>WCC ≤3.5 × 10
                           <sup>9</sup>/L
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Neutrophils ≤1.5 × 10
                           <sup>9</sup>/L
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Platelets ≤100 × 10
                           <sup>9</sup>/L
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>ALT &gt;2 times ULN for the laboratory conducting the test.</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Creatinine &gt;1.5 times ULN for the laboratory conducting the tested</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>eGFR &lt;30 mL/minute</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 2</p>
            </div>
            <caption>
               <p>Participant flowchart. </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Participant flowchart.</b> EQ-5D, EuroQol 5D-5 L; HADS, hospital anxiety and depression scale; ICOAP, intermittent
                  and constant osteoarthritis pain scale; MRI, magnetic resonance imaging; MTX, methotrexate;
                  NHS, National Health Service; NRS, numerical rating scale; OA QoL, osteoarthritis
                  quality of life; PIS, patient information sheet; SF-12, Short Form-12; WOMAC, Western
                  Ontario and McMaster Osteoarthritis Index. Treatment assignment and allocation concealment.
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
         <p>Identical over-encapsulated MTX and placebo capsules will be produced to ensure allocation
            concealment. Upon production, study medication will be packed into bulk numbered bottles
            according to a randomization schedule. This will be prepared by the contract manufacturer
            using a computerized random number generator, thereby guaranteeing full allocation
            concealment. Study medication will be issued in numerical order by the pharmacy. Participants
            in each site will be randomly assigned to the intervention arm or the placebo arm
            in a ratio of 1:1, and the randomization will be double-blind.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Blinding</h3>
         </div>
         <p>Investigators and participants will remain blinded throughout the trial. Emergency
            unblinding will be allowed in limited situations that impact on the safety of study
            participants. Code-break envelopes for the full randomization schedule will be maintained
            by the Leeds General Infirmary pharmacy, and pharmacies at other sites will hold code-break
            envelopes for their respective participants. A 24-hour code-break telephone line will
            also be established in case of the need for emergency out-of-hours unblinding. Participants
            who are unblinded will be withdrawn from treatment but will continue to be followed
            as per the planned follow-up schedule, unless they request to fully withdraw from
            the trial.
         </p>
         <div id="">
            <div tagx="st">
               <h4>Maintaining the treatment blind</h4>
            </div>
            <p>Given the possible toxicities related to MTX, there is potential for investigators
               reviewing blood results to become aware of treatment. Therefore, patient-reported
               outcomes will be completed before any changes in dose or results of blood monitoring
               are discussed with participants. Where possible, members of staff with knowledge of
               blood results will not be responsible for administering patient questionnaires.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data collection</h3>
         </div>
         <p>All data will be collected on standardized CRFs, which will be completed by site staff,
            verified by the principal investigator, and returned to the clinical trials unit for
            data entry. Study sites will also return a patient non-identifiable participant log
            and study drug dispensing log to the clinical trials unit.
         </p>
         <div id="">
            <div tagx="st">
               <h4>Patient reported, clinical and imaging assessments</h4>
            </div>
            <p>In addition to the patient-reported measures of pain, function and quality-of-life
               and imaging outcome measures described above and outlined in Table 
               <span tagx="tblr">2</span>, a number of additional data elements will be collected during the trial. At the
               baseline visit, medical history and demographic data, including smoking and alcohol
               consumption, employment and family history of knee OA will be collected. Physical
               examination and vital signs, including height and weight, will be collected at screening,
               six and 12 months. A clinical examination of the knee will also be conducted at the
               baseline visit. This will assess effusion on a zero to three scale, where one is positive
               bulge sign, two is positive fluctuance (balloon sign) and three is tense effusion,
               and compartmental (medial tibiofemoral (MTF), lateral tibiofemoral (LTF) or patellofemoral
               (PF)) tenderness, also measured on a zero to three scale. The specific tools used
               to capture each data element are further detailed in Table 
               <span tagx="tblr">2</span>.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Safety assessments</h4>
            </div>
            <p>Adverse events will be recorded throughout the study. Intensity and relationship to
               the study medication will be ascribed.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Blood and urine safety assessment</h4>
            </div>
            <p>Safety of therapy will be assessed according to regional monitoring guidelines and
               will be determined by treatment strategy. Full blood count (FBC), liver function test
               (LFT) and urea and electrolytes (U&amp;E) tests will be performed at screening, every
               two weeks for the first eight weeks, and every four weeks thereafter. If a patient’s
               results remain abnormal despite action (such as reducing their MTX dose), or at clinician
               discretion, then study medication will be stopped. For the purposes of this study,
               abnormal is defined as: haemoglobin ≤8.5 g/dL; white cell count (WCC) ≤3.5 × 10
               <sup>9</sup>/L; neutrophils ≤1.5 × 10
               <sup>9</sup>/L; platelets ≤100 × 10
               <sup>9</sup>/L; alanine aminotransferase (ALT) &gt; two times the upper limit of normal (ULN) for
               the laboratory conducting the test; creatinine &gt;1.5 times the ULN for the laboratory
               conducting the test and estimated glomerular filtration rate (eGFR) &lt;30 mL/minute.
            </p>
            <p>C-reactive protein (CRP), anti-cyclic citrullinated protein (anti-CCP) and rheumatoid
               factor (RF) tests will be performed at screening. Anti-CCP and RF results from the
               previous 12 months may be used if these are available. A dipstick urinalysis will
               be performed at screening to check for evidence of leucocytes, blood or protein, to
               exclude urine infection. A urine dipstick pregnancy test will be performed for female
               participants with child-bearing potential, and appropriate contraceptive methods documented
               for those at risk.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data integrity and management</h3>
         </div>
         <p>All data obtained will be kept strictly confidential and will be stored electronically
            on a database with secured and restricted access. Datasets for each subject will be
            identified by the participant trial identification number only.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Withdrawal</h3>
         </div>
         <p>All participants have the right to withdraw consent at any time without prejudice.
            At the time of withdrawal of consent, a full efficacy and safety evaluation should
            be performed if the participant consents. Participants who withdraw will be asked
            to complete the questionnaires as per the next planned study visit. At a participant’s
            request, their data collected up to the point of withdrawal can also be withdrawn
            from the trial and will not be used in the final analysis. Participants who withdraw
            will return to routine care in the rheumatology and musculoskeletal out-patient clinics.
         </p>
         <p>In the event that a patient is unable to tolerate 7.5 mg of MTX, they will be withdrawn
            from treatment but will continue to be followed up on as per the planned follow-up
            schedule, unless they request to fully withdraw from the trial.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study site staff training</h3>
         </div>
         <p>A centralized introduction and training session was held for all principal investigators
            and site staff. In addition to this, a site initiation visit will be held at all sites,
            in order to provide specific training to all staff involved in the study ahead of
            recruitment. Pre-study training will be conducted to ensure robustness of MRI acquisition.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Trial site monitoring</h3>
         </div>
         <p>The trial will be overseen and monitored by the York Trials Unit on behalf of the
            Sponsor, the University of Leeds. Each site will be assessed prior to site setup,
            and visited again once the third participant is recruited or at 20 weeks after the
            start of recruitment at site, whichever is sooner. The PROMOTE trial was assessed
            as low risk by the Medicines and Healthcare Products Regulatory Agency (MHRA), and
            therefore in addition to the single monitoring visit, procedures for central monitoring
            at the clinical trials unit have been put in place. This will mainly involve cross-checking
            logs returned from the research team and site pharmacy for consistency. A data monitoring
            and ethics committee will provide independent oversight to ensure data quality and
            compliance with the trial protocol.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical analysis</h3>
         </div>
         <p>Full details of the statistical methods will be written in an approved statistical
            analysis plan prior to any data analysis.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Primary endpoint analysis</h3>
         </div>
         <p>The primary analysis will be conducted on the intention-to-treat population, including
            all randomized participants in the groups to which they were randomized. A per protocol
            population (excluding major protocol violations) will be used to check the robustness
            of the primary analyses. The safety population will consist of all patients receiving
            at least one dose of the study drug.
         </p>
         <p>The first 30 participants (included in the internal pilot study) will be included
            in the main trial analysis along with the rest of the participants. Wittes and Brittain
            show that sample size re-estimation using an internal pilot study has minimum impact
            on the overall type I error, therefore an alpha level of 0.05 will still be used for
            the primary analysis 
            <span tagx="abbrgrp">
               <span tagx="abbr">57</span>
            </span>.
         </p>
         <p>The pilot phase analysis, which will be conducted after primary outcome data becomes
            available for the thirtieth participant, will include the following:
         </p>
         <p>1. Assessment of the variability of the primary outcome measure, the estimate (SD)
            will be used to update the sample size calculation;
         </p>
         <p>2. Consent rate (out of the number of information packs sent out during the pilot
            phase);
         </p>
         <p>3. Retention rates associated with each treatment and</p>
         <p>4. Return rate for the six-month outcome assessment.</p>
         <p>The primary analysis for the main study will be conducted using linear regression
            adjusting for the baseline measure. Treatment groups will be compared at six months
            with respect to their average overall knee pain severity over the previous week.
         </p>
         <p>All secondary analyses will be conducted using linear or logistic regression, depending
            on the type of outcome measure, adjusting for the same covariates as the primary analysis.
            The intention-to-treat population will be used for all secondary analyses. All secondary
            outcomes will be described descriptively (mean, SD, median, minimum and maximum for
            continuous data and counts and percentages for categorical data). The Short Form-12
            questionnaire will be summarized for all components. To minimise multiple testing,
            only the overall physical component score and mental component score will be analysed,
            using the same analysis methods as for the primary outcome. For continuous outcomes
            the regression model assumptions will be checked and, if necessary, data will be transformed
            prior to analysis if this improves the model fit, or normalises the distribution of
            residuals.
         </p>
         <p>Adverse events will be coded according to the MedDRA adverse event dictionary. The
            overall incidence of serious adverse events and adverse events and number and proportion
            of patients reporting such events will be summarized by treatment group. Adverse events
            (including serious adverse events) will be summarized by the number and percentage
            of subjects who experienced the event by system organ class and preferred term. Subjects
            will only be counted once. If a subject reports the same adverse event more than once
            then the maximum grade and strongest causal relationship to study treatment will be
            used for the summary tables. Adverse events will also be summarized by severity and
            by relationship to study drug. All adverse events will be included in individual subject
            line listings.
         </p>
         <p>Analysis of MRI endpoints will be exploratory. Treatment groups will be compared with
            respect to changes in synovitis, cartilage and bone using linear regression models
            with adjustment for the same covariates as the primary analysis. Linear regression
            models will also be used to explore the association between symptom outcome and baseline
            MRI measurements. Changes in MR features and the relationship of these changes with
            symptom changes will be explored descriptively.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Health economics analysis</h3>
         </div>
         <p>An economic analysis will be undertaken in order to determine the cost-effectiveness
            of oral MTX for the treatment of knee OA. A cost-utility analysis will also be undertaken
            to explore the impact on health-related quality of life. The analyses will be conducted
            from the perspective of the United Kingdom NHS and Personal Social Services (PSS),
            in line with National Institute for Health and Care Excellence recommendations 
            <span tagx="abbrgrp">
               <span tagx="abbr">58</span>
            </span>.
         </p>
         <p>Health benefits for the economic evaluation will be measured in terms of pain reduction
            and QALYs. The QALY is a generic outcome which enables decision makers to compare
            across different disease areas. QALYs will be generated from the EuroQol EQ-5D-5 L
            for use in the cost-utility analysis, and will be estimated by measuring the area
            under the curve 
            <span tagx="abbrgrp">
               <span tagx="abbr">59</span>
            </span>. Utility data will be collected at the same time points as for clinical outcomes
            (at baseline, six months and 12 months).
         </p>
         <p>Costs of the intervention, control and the total health care costs during the treatment
            and follow-up period will be assessed, including costs of adverse events and medications.
            Health service resource use will be collected via a self-reported resource use questionnaire,
            with national costs applied to the quantities of resources utilized, for example using
            NHS Reference Costs 
            <span tagx="abbrgrp">
               <span tagx="abbr">60</span>
            </span> and Unit Costs of Health and Social Care 
            <span tagx="abbrgrp">
               <span tagx="abbr">61</span>
            </span>. The unit costs of medications will be sourced from the British National Formulary
            
            <span tagx="abbrgrp">
               <span tagx="abbr">62</span>
            </span>.
         </p>
         <p>The within-trial analysis will use regression methods to allow for the correlation
            between cost and outcome data generated from the trial, with adjustment for covariates.
            A cost-effectiveness analysis will determine the cost per unit of reduction in knee
            pain score (as measured on the NRS). A cost-utility analysis will be undertaken to
            generate the cost per QALY. The results will be presented in terms of incremental
            cost-effectiveness ratios (ICERs). Future costs and outcomes will not be discounted
            due to the trial follow-up being one year. Cost-effectiveness acceptability curves
            will be produced to explore the probability that MTX will be cost-effective at different
            cost-effectiveness thresholds 
            <span tagx="abbrgrp">
               <span tagx="abbr">63</span>
            </span>.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>Current medical therapy does not provide satisfactory pain relief in the majority
         of people with OA 
         <span tagx="abbrgrp">
            <span tagx="abbr">64</span>
         </span>; with the rapidly ageing population the prevalence of OA will continue to rise over
         the next decade. Unless the barriers to successful treatment of OA are overcome, the
         already considerable social and economic burden will soon reach an unsustainable level.
         The last decade has seen major advances in understanding OA pathology. MRI has demonstrated
         that synovial inflammation is common in OA and is related to symptoms. MTX is the
         most common agent used to treat synovitis in RA and because of its favourable efficacy,
         long-term retention rates, low cost and established track record it has become the
         standard by which other DMARDs are evaluated, supporting our choice to use MTX rather
         than any other DMARD for a trial in OA. Since the design of this study and conduct
         of the systematic literature review, a single-centre randomized controlled trial of
         MTX in knee OA has been published 
         <span tagx="abbrgrp">
            <span tagx="abbr">65</span>
         </span>. The study demonstrated a clinically relevant reduction in knee pain and physical
         function in the intervention group compared with the placebo group at 28 weeks. A
         significantly higher proportion of patients in the MTX group (53%) showed a reduction
         in VAS of more than 20 mm compared to the placebo group (24%; 
         <i>P</i> = 0.018). The positive findings of this study reinforce the potential of MTX as a
         treatment for OA. However, given the substantial impact that using MTX for treating
         OA would have on clinical practice, a large multi-centre confirmatory study is essential.
         The PROMOTE trial has been designed to be pragmatic in nature so as to answer the
         question as to whether MTX is a valuable addition to the overall management of patients
         with OA.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>Recruitment to the trial began in June 2014. Follow-up of participants is in progress
         and is expected to be completed in December 2016.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>AICAR: Aminoimidazole carboxamide ribonucleotide</p>
      <p>ALT: Alanine aminotransferase</p>
      <p>CCG: Clinical Commissioning Group</p>
      <p>CCP: Cyclic citrullinated protein</p>
      <p>CCRN: Comprehensive Clinical Research Network</p>
      <p>CPPD: Calcium pyrophosphate crystal disease</p>
      <p>CRF: Case report form</p>
      <p>CRP: C-reactive protein</p>
      <p>CVD: Cardiovascular disease</p>
      <p>DMARD: Disease modifying anti-rheumatic drug</p>
      <p>eGFR: Estimated glomerular filtration rate</p>
      <p>FBC: Full blood count</p>
      <p>GP: General practitioner</p>
      <p>HADS: Hospital Anxiety and Depression Scale</p>
      <p>IA: Intra-articular</p>
      <p>ICER: Incremental cost-effectiveness ratio</p>
      <p>ICOAP: Intermittent and Constant Osteoarthritis Pain</p>
      <p>IL: Interleukin</p>
      <p>LFT: Liver function test</p>
      <p>LTF: Lateral tibiofemoral</p>
      <p>MHRA: Medicines and Healthcare Products Regulatory Agency</p>
      <p>MOAKS: MRI Osteoarthritis Knee Score</p>
      <p>MRI: Magnetic resonance imaging</p>
      <p>MTF: Medial tibiofemoral</p>
      <p>MTX: Methotrexate</p>
      <p>NHS: National Health Service</p>
      <p>NICE: National Institute for Health and Care Excellence</p>
      <p>NIMP: Non-Investigational Medicinal Product</p>
      <p>NRS: Numerical rating scale</p>
      <p>NSAID: Non-steroidal anti-inflammatory drug</p>
      <p>OA: Osteoarthritis</p>
      <p>OA QoL: Osteoarthritis Quality of Life Scale</p>
      <p>PF: Patellofemoral</p>
      <p>PICS: Patient Identification Centres</p>
      <p>PsA: Psoriatic arthritis</p>
      <p>PSS: Personal Social Services</p>
      <p>QALY: Quality-adjusted life year</p>
      <p>RA: Rheumatoid arthritis</p>
      <p>RF: Rheumatoid factor</p>
      <p>SD: Standard deviation</p>
      <p>TNF: Tumour necrosis factor</p>
      <p>U&amp;E: Urea and electrolytes</p>
      <p>ULN: Upper limit of normal</p>
      <p>VAS: Visual analogue scale</p>
      <p>WCC: White cell count</p>
      <p>WOMAC: Western Ontario and McMaster Universities Index of OA</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>The authors declare they have no competing interests.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>PGC conceived the study. SRK, PT, NKA, MB, FB, KC, MD, CJE, TG, AJG, MG, CEH,RH, RM,
         TWO, ER, DLS, FEW, DJT and PGC participated in its design and coordination, and performed
         the research. SRK and PT drafted the manuscript. All authors revised the manuscript
         and gave final approval of the version to be submitted.
      </p>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>The PROMOTE trial is funded by an Arthritis Research UK Clinical Studies Grant (reference
               number: 20186). The authors acknowledge the support of the National Institute for
               Health Research, through the Comprehensive Clinical Research Network (CCRN). Please
               do not hesitate to contact the CCRN Portfolio team at ccrn.portfolio@nihr.ac.uk should
               you require further information.
            </p>
            <p>SRK and PGC are part funded by the National Institute for Health Research (NIHR) through
               the Leeds Musculoskeletal Biomedical Research Unit. This paper presents independent
               research funded by the NIHR. The views expressed are those of the authors and not
               necessarily those of the NHS, the NIHR or the Department of Health.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,
                  1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murray</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vos</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lozano</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Naghavi</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Flaxman</span>
                  <span tagx="fnm">AD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Michaud</span>
                  <span tagx="fnm">C</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">380</span>
            <span tagx="issue">9859</span>
            <span tagx="fpage">2197</span>
            <span tagx="lpage">223</span>
            <div tagx="note"> doi:10.1016/S0140-6736(12)61689-4</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(12)61689-4</span>
                  <span tagx="pubid">23245608</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries
                  1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Vos</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Flaxman</span>
                  <span tagx="fnm">AD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Naghavi</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lozano</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Michaud</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ezzati</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">380</span>
            <span tagx="issue">9859</span>
            <span tagx="fpage">2163</span>
            <span tagx="lpage">96</span>
            <div tagx="note"> doi:10.1016/S0140-6736(12)61729-2</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(12)61729-2</span>
                  <span tagx="pubid">23245607</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Lifetime risk of symptomatic knee osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schwartz</span>
                  <span tagx="fnm">TA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Helmick</span>
                  <span tagx="fnm">CG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Renner</span>
                  <span tagx="fnm">JB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tudor</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koch</span>
                  <span tagx="fnm">G</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">59</span>
            <span tagx="issue">9</span>
            <span tagx="fpage">1207</span>
            <span tagx="lpage">13</span>
            <div tagx="note"> doi:10.1002/art.24021</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/art.24021</span>
                  <span tagx="pubid">18759314</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The economic burden of osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bitton</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Am J Manag Care</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">15</span>
            <span tagx="issue">Suppl 8</span>
            <span tagx="fpage">S230</span>
            <span tagx="lpage">5</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">19817509</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Care</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">OA Nations Survey</span>
            <span tagx="pubdate">2003</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Health economics in the field of osteoarthritis: An Expert’s consensus paper from
                  the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
                  (ESCEO)
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hiligsmann</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cooper</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Arden</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boers</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Branco</span>
                  <span tagx="fnm">JC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Luisa Brandi</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Semin Arthritis Rheum</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">43</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">303</span>
            <span tagx="lpage">13</span>
            <div tagx="note"> doi:10.1016/j.semarthrit.2013.07.003</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.semarthrit.2013.07.003</span>
                  <span tagx="pubid">23992801</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">National Institute for Health and Care Excellence. Osteoarthritis: care and management
               in adults. NICE Clinical Guideline 177. February 2014. 
               <a href="http://www.nice.org.uk/guidance/CG177">http://www.nice.org.uk/guidance/CG177</a>. Accessed 4 Aug 2014.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>OARSI guidelines for the non-surgical management of knee osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">McAlindon</span>
                  <span tagx="fnm">TE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bannuru</span>
                  <span tagx="fnm">RR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sullivan</span>
                  <span tagx="fnm">MC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Arden</span>
                  <span tagx="fnm">NK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Berenbaum</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bierma-Zeinstra</span>
                  <span tagx="fnm">SM</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Osteoarthritis Cartilage</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">22</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">363</span>
            <span tagx="lpage">88</span>
            <div tagx="note"> doi:10.1016/j.joca.2014.01.003</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.joca.2014.01.003</span>
                  <span tagx="pubid">24462672</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic
                  and pharmacologic therapies in osteoarthritis of the hand, hip, and knee
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hochberg</span>
                  <span tagx="fnm">MC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">RD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">April</span>
                  <span tagx="fnm">KT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Benkhalti</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guyatt</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McGowan</span>
                  <span tagx="fnm">J</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Care Res (Hoboken)</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">64</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">465</span>
            <span tagx="lpage">74</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/acr.21596</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Conaghan PG, Porcheret M, Kingsbury SR, Gammon A, Soni A, Hurley M et al. Impact and
               therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey. Clin Rheumatol.
               2014. doi:10.1007/s10067-014-2692-1.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">National population projections, 2008-based. Office for National Statistics. 2009.
               
               <a href="http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2008-based-projections/index.html">http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2008-based-projections/index.html</a>. Accessed 19 Feb 2015.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Proceedings of the bone and joint decade 2000–2010 for prevention and treatment of
               musculo-skeletal disorders; 1998 April 17–18; Lund, Sweden. Acta Orthop Scand Suppl.
               1998;281:1–86.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1:
                  prevalence of inflammation in osteoarthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">D’Agostino</span>
                  <span tagx="fnm">MA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Le Bars</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baron</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grassi</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Martin-Mola</span>
                  <span tagx="fnm">E</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">64</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1703</span>
            <span tagx="lpage">9</span>
            <div tagx="note"> doi:10.1136/ard.2005.037994</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.2005.037994</span>
                  <span tagx="pubid">15878903</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Magnetic resonance imaging-determined synovial membrane and joint effusion volumes
                  in rheumatoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic
                  appearance of the synovium
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ostergaard</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stoltenberg</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lovgreen-Nielsen</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Volck</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jensen</span>
                  <span tagx="fnm">CH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lorenzen</span>
                  <span tagx="fnm">I</span>
               </li>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">1997</span>
            <span tagx="volume">40</span>
            <span tagx="issue">10</span>
            <span tagx="fpage">1856</span>
            <span tagx="lpage">67</span>
            <div tagx="note"> doi:10.1002/1529-0131(199710)40:10&lt;1856::AID-ART20&gt;3.0.CO;2-3</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/art.1780401020</span>
                  <span tagx="pubid">9336422</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>MR imaging of the arthritic knee: improved discrimination of cartilage, synovium,
                  and effusion with pulsed saturation transfer and fat-suppressed T1-weighted sequences
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Peterfy</span>
                  <span tagx="fnm">CG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Majumdar</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lang</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Dijke</span>
                  <span tagx="fnm">CF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sack</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Genant</span>
                  <span tagx="fnm">HK</span>
               </li>
            </ul>
            <span tagx="source">Radiology</span>
            <span tagx="pubdate">1994</span>
            <span tagx="volume">191</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">413</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1148/radiology.191.2.8153315</span>
                  <span tagx="pubid">8153315</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship
                  to structural pathology and symptoms
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Keen</span>
                  <span tagx="fnm">HI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wakefield</span>
                  <span tagx="fnm">RJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grainger</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hensor</span>
                  <span tagx="fnm">EM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Emery</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">PG</span>
               </li>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">59</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1756</span>
            <span tagx="lpage">63</span>
            <div tagx="note"> doi:10.1002/art.24312</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/art.24312</span>
                  <span tagx="pubid">19035429</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Knee effusions, popliteal cysts, and synovial thickening: association with knee pain
                  in osteoarthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hill</span>
                  <span tagx="fnm">CL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gale</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chaisson</span>
                  <span tagx="fnm">CE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Skinner</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kazis</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gale</span>
                  <span tagx="fnm">ME</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">28</span>
            <span tagx="issue">6</span>
            <span tagx="fpage">1330</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">11409127</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage
                  loss in knee osteoarthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hill</span>
                  <span tagx="fnm">CL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hunter</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Niu</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Clancy</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guermazi</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Genant</span>
                  <span tagx="fnm">H</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">66</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1599</span>
            <span tagx="lpage">603</span>
            <div tagx="note"> doi:10.1136/ard.2006.067470</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.2006.067470</span>
                  <span tagx="pubid">17491096</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Anticytokine therapy for osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Goldring</span>
                  <span tagx="fnm">MB</span>
               </li>
            </ul>
            <span tagx="source">Expert Opin Biol Ther</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">1</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">817</span>
            <span tagx="lpage">29</span>
            <div tagx="note"> doi:10.1517/14712598.1.5.817</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1517/14712598.1.5.817</span>
                  <span tagx="pubid">11728217</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Synovial membrane inflammation and cytokine production in patients with early osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Smith</span>
                  <span tagx="fnm">MD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Triantafillou</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Parker</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Youssef</span>
                  <span tagx="fnm">PP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Coleman</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">1997</span>
            <span tagx="volume">24</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">365</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">9034998</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Synovial inflammation in patients with early osteoarthritis of the knee</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Myers</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brandt</span>
                  <span tagx="fnm">KD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ehlich</span>
                  <span tagx="fnm">JW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Braunstein</span>
                  <span tagx="fnm">EM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shelbourne</span>
                  <span tagx="fnm">KD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Heck</span>
                  <span tagx="fnm">DA</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">1990</span>
            <span tagx="volume">17</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1662</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">2084242</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Brandt</span>
                  <span tagx="fnm">KD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mazzuca</span>
                  <span tagx="fnm">SA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Buckwalter</span>
                  <span tagx="fnm">KA</span>
               </li>
            </ul>
            <span tagx="source">Rheumatology (Oxford)</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">45</span>
            <span tagx="issue">11</span>
            <span tagx="fpage">1389</span>
            <span tagx="lpage">94</span>
            <div tagx="note"> doi:10.1093/rheumatology/kel100</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/rheumatology/kel100</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients
                  with knee osteoarthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gineyts</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mo</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ko</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Henriksen</span>
                  <span tagx="fnm">DB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Curtis</span>
                  <span tagx="fnm">SP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gertz</span>
                  <span tagx="fnm">BJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">63</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">857</span>
            <span tagx="lpage">61</span>
            <div tagx="note"> doi:10.1136/ard.2003.007302</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.2003.007302</span>
                  <span tagx="pubid">15194584</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Osteoarthritis: new insights. Part 1: the disease and its risk factors</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Felson</span>
                  <span tagx="fnm">DT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lawrence</span>
                  <span tagx="fnm">RC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dieppe</span>
                  <span tagx="fnm">PA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hirsch</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Helmick</span>
                  <span tagx="fnm">CG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jordan</span>
                  <span tagx="fnm">JM</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Intern Med</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">133</span>
            <span tagx="issue">8</span>
            <span tagx="fpage">635</span>
            <span tagx="lpage">46</span>
            <div tagx="note"> doi:200010170–00016</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7326/0003-4819-133-8-200010170-00016</span>
                  <span tagx="pubid">11033593</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of joint lavage and steroid injection in patients with osteoarthritis of the
                  knee: results of a multicenter, randomized, controlled trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ravaud</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moulinier</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Giraudeau</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ayral</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guerin</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Noel</span>
                  <span tagx="fnm">E</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">42</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">475</span>
            <span tagx="lpage">82</span>
            <div tagx="note"> doi:10.1002/1529-0131(199904)42:3&lt;475::AID-ANR12&gt;3.0.CO;2-S</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/1529-0131(199904)42:3&lt;475::AID-ANR12&gt;3.0.CO;2-S</span>
                  <span tagx="pubid">10088770</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intraarticular corticosteroid for treatment of osteoarthritis of the knee</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bellamy</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Campbell</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Robinson</span>
                  <span tagx="fnm">V</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gee</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bourne</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wells</span>
                  <span tagx="fnm">G</span>
               </li>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">2</span>
            <div tagx="note">Article ID CD005328 doi:10.1002/14651858.CD005328.pub2</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">16625636</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical
                  predictors of response
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jones</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Doherty</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">1996</span>
            <span tagx="volume">55</span>
            <span tagx="issue">11</span>
            <span tagx="fpage">829</span>
            <span tagx="lpage">32</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.55.11.829</span>
                  <span tagx="pubid">8976640</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic
                  and pharmacologic therapies in osteoarthritis of the hand, hip, and knee
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hochberg</span>
                  <span tagx="fnm">MC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">RD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">April</span>
                  <span tagx="fnm">KT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Benkhalti</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guyatt</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McGowan</span>
                  <span tagx="fnm">J</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Care Res</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">64</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">455</span>
            <span tagx="lpage">74</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/acr.21596</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis:
                  a systematic literature review
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Westlake</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Colebatch</span>
                  <span tagx="fnm">AN</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baird</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kiely</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Quinn</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Choy</span>
                  <span tagx="fnm">E</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Rheumatology (Oxford)</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">49</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">295</span>
            <span tagx="lpage">307</span>
            <div tagx="note"> doi:10.1093/rheumatology/kep366</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/rheumatology/kep366</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methotrexate in psoriatic arthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mease</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">Bull Hosp Jt Dis (2013)</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">71</span>
            <span tagx="issue">Suppl 1</span>
            <span tagx="fpage">S41</span>
            <span tagx="lpage">5</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Adenosine: an endogenous regulator of innate immunity</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hasko</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cronstein</span>
                  <span tagx="fnm">BN</span>
               </li>
            </ul>
            <span tagx="source">Trends Immunol</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">25</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">33</span>
            <span tagx="lpage">9</span>
            <div tagx="note"> doi:S1471490603003582</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.it.2003.11.003</span>
                  <span tagx="pubid">14698282</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cronstein</span>
                  <span tagx="fnm">BN</span>
               </li>
            </ul>
            <span tagx="source">Pharmacol Rev</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">57</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">163</span>
            <span tagx="lpage">72</span>
            <div tagx="note"> doi:10.1124/pr.57.2.3</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1124/pr.57.2.3</span>
                  <span tagx="pubid">15914465</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Weinblatt</span>
                  <span tagx="fnm">ME</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kaplan</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Germain</span>
                  <span tagx="fnm">BF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Block</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Solomon</span>
                  <span tagx="fnm">SD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Merriman</span>
                  <span tagx="fnm">RC</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">1994</span>
            <span tagx="volume">37</span>
            <span tagx="issue">10</span>
            <span tagx="fpage">1492</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/art.1780371013</span>
                  <span tagx="pubid">7945475</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate
                  in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind,
                  placebo-controlled study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">van Ede</span>
                  <span tagx="fnm">AE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Laan</span>
                  <span tagx="fnm">RF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rood</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Huizinga</span>
                  <span tagx="fnm">TW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van de Laar</span>
                  <span tagx="fnm">MA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Denderen</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">44</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">1515</span>
            <span tagx="lpage">24</span>
            <div tagx="note"> doi:10.1002/1529-0131(200107)44:7&lt;1515::AID-ART273&gt;3.0.CO;2-7</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/1529-0131(200107)44:7&lt;1515::AID-ART273&gt;3.0.CO;2-7</span>
                  <span tagx="pubid">11465701</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid
                  arthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Schnabel</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Herlyn</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Burchardi</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Reinhold-Keller</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gross</span>
                  <span tagx="fnm">WL</span>
               </li>
            </ul>
            <span tagx="source">Rheumatol Int</span>
            <span tagx="pubdate">1996</span>
            <span tagx="volume">15</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">195</span>
            <span tagx="lpage">200</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/BF00290521</span>
                  <span tagx="pubid">8717103</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A prospective study of the long-term efficacy and toxicity of low-dose methotrexate
                  in rheumatoid arthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Salaffi</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carotti</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sartini</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cervini</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">Clin Exp Rheumatol</span>
            <span tagx="pubdate">1995</span>
            <span tagx="volume">13</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">23</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">7774099</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Low-dose methotrexate compared to placebo in the treatment of knee osteoarthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">de Holanda</span>
                  <span tagx="fnm">HT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pollak</span>
                  <span tagx="fnm">DF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pucinelli</span>
                  <span tagx="fnm">ML</span>
               </li>
            </ul>
            <span tagx="source">Rev Bras Reumatol</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">47</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">334</span>
            <span tagx="lpage">40</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1590/S0482-50042007000500008</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methotrexate in the treatment of erosive OA of the hands</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Pavelka</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Olejarova</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pavelkova</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">65</span>
            <span tagx="issue">Suppl II</span>
            <span tagx="fpage">402</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition
                  disease: an exploratory analysis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chollet-Janin</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Finckh</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dudler</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guerne</span>
                  <span tagx="fnm">PA</span>
               </li>
            </ul>
            <span tagx="source">Arthritis Rheum</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">56</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">688</span>
            <span tagx="lpage">92</span>
            <div tagx="note"> doi:10.1002/art.22389</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/art.22389</span>
                  <span tagx="pubid">17265505</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methotrexate for pain relief in knee osteoarthritis: an open-label study</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wenham</span>
                  <span tagx="fnm">CY</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grainger</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hensor</span>
                  <span tagx="fnm">EM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Caperon</span>
                  <span tagx="fnm">AR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ash</span>
                  <span tagx="fnm">ZR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">PG</span>
               </li>
            </ul>
            <span tagx="source">Rheumatology (Oxford)</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">52</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">888</span>
            <span tagx="lpage">92</span>
            <div tagx="note"> doi:10.1093/rheumatology/kes386</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/rheumatology/kes386</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The effects of high-dose methotrexate on the development of cartilage lesions in a
                  lapine model of osteoarthrosis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Neidel</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schroers</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sintermann</span>
                  <span tagx="fnm">F</span>
               </li>
            </ul>
            <span tagx="source">Arch Orthop Trauma Surg</span>
            <span tagx="pubdate">1998</span>
            <span tagx="volume">117</span>
            <span tagx="issue">4–5</span>
            <span tagx="fpage">265</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/s004020050243</span>
                  <span tagx="pubid">9581258</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The effects of methotrexate on normal and osteoarthritic lapine articular cartilage</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mannoni</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">RD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Muniz</span>
                  <span tagx="fnm">OE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Serni</span>
                  <span tagx="fnm">U</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dean</span>
                  <span tagx="fnm">DD</span>
               </li>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">1993</span>
            <span tagx="volume">20</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">849</span>
            <span tagx="lpage">55</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">8336311</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Multinational evidence-based recommendations for the use of methotrexate in rheumatic
                  disorders with a focus on rheumatoid arthritis: integrating systematic literature
                  research and expert opinion of a broad international panel of rheumatologists in the
                  3E Initiative
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Visser</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Katchamart</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Loza</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Martinez-Lopez</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Salliot</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Trudeau</span>
                  <span tagx="fnm">J</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">68</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">1086</span>
            <span tagx="lpage">93</span>
            <div tagx="note"> doi:10.1136/ard.2008.094474</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.2008.094474</span>
                  <span tagx="pubid">19033291</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:
                  a systematic review of the literature
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Visser</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van der Heijde</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">68</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">1094</span>
            <span tagx="lpage">9</span>
            <div tagx="note"> doi:10.1136/ard.2008.092668</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/ard.2008.092668</span>
                  <span tagx="pubid">19033290</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Folic acid and folinic acid for reducing side effects in patients receiving methotrexate
                  for rheumatoid arthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Shea</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Swinden</span>
                  <span tagx="fnm">MV</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tanjong Ghogomu</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ortiz</span>
                  <span tagx="fnm">Z</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Katchamart</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rader</span>
                  <span tagx="fnm">T</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">5</span>
            <div tagx="note">Article ID CD000951 doi:10.1002/14651858.CD000951.pub2</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">23728635</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A psychometric evaluation of 4-point and 6-point Likert-type scales in relation to
                  reliability and validity applied psychological measurements
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chang</span>
                  <span tagx="fnm">L</span>
               </li>
            </ul>
            <span tagx="source">Appl Psychol Meas</span>
            <span tagx="pubdate">1994</span>
            <span tagx="volume">18</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">205</span>
            <span tagx="lpage">15</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1177/014662169401800302</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to
                  treatment effects in the REPORT database
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dworkin</span>
                  <span tagx="fnm">RH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Peirce-Sandner</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Turk</span>
                  <span tagx="fnm">DC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McDermott</span>
                  <span tagx="fnm">MP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gibofsky</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Simon</span>
                  <span tagx="fnm">LS</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Osteoarthritis Cartilage</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">19</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">483</span>
            <span tagx="lpage">92</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.joca.2011.02.020</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Core outcome measures for chronic pain clinical trials: IMMPACT recommendations</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dworkin</span>
                  <span tagx="fnm">RH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Turk</span>
                  <span tagx="fnm">DC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Farrar</span>
                  <span tagx="fnm">JT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Haythornthwaite</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jensen</span>
                  <span tagx="fnm">MP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Katz</span>
                  <span tagx="fnm">NP</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Pain</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">113</span>
            <span tagx="issue">1–2</span>
            <span tagx="fpage">9</span>
            <span tagx="lpage">19</span>
            <div tagx="note"> doi:10.1016/j.pain.2004.09.012</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.pain.2004.09.012</span>
                  <span tagx="pubid">15621359</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Core outcome domains for chronic pain clinical trials: IMMPACT recommendations</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Turk</span>
                  <span tagx="fnm">DC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dworkin</span>
                  <span tagx="fnm">RH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Allen</span>
                  <span tagx="fnm">RR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bellamy</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brandenburg</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carr</span>
                  <span tagx="fnm">DB</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Pain</span>
            <span tagx="pubdate">2003</span>
            <span tagx="volume">106</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">337</span>
            <span tagx="lpage">45</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.pain.2003.08.001</span>
                  <span tagx="pubid">14659516</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Identifying important outcome domains for chronic pain clinical trials: an IMMPACT
                  survey of people with pain
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Turk</span>
                  <span tagx="fnm">DC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dworkin</span>
                  <span tagx="fnm">RH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Revicki</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Harding</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Burke</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cella</span>
                  <span tagx="fnm">D</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Pain</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">137</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">276</span>
            <span tagx="lpage">85</span>
            <div tagx="note"> doi:10.1016/j.pain.2007.09.002</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.pain.2007.09.002</span>
                  <span tagx="pubid">17937976</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis
                  Knee Score). Osteoarthritis Cartilage. 2011;19(8):990–1002. Erratum in
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hunter</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guermazi</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lo</span>
                  <span tagx="fnm">GH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grainger</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">PG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boudreau</span>
                  <span tagx="fnm">RM</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Osteoarthritis Cartilage</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">19</span>
            <span tagx="issue">9</span>
            <span tagx="fpage">1168</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.joca.2011.08.001</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A novel method for bone area measurement provides new insights into osteoarthritis
                  and its progression
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bowes</span>
                  <span tagx="fnm">MA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vincent</span>
                  <span tagx="fnm">GR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wolstenholme</span>
                  <span tagx="fnm">CB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">PG</span>
               </li>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2015</span>
            <span tagx="volume">74</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">519</span>
            <span tagx="lpage">25</span>
            <div tagx="note"> doi:10.1136/annrheumdis-2013-204052</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/annrheumdis-2013-204052</span>
                  <span tagx="pubid">24306109</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Clinical importance of changes in chronic pain intensity measured on an 11-point numerical
                  pain rating scale
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Farrar</span>
                  <span tagx="fnm">JT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Young</span>
                  <span tagx="fnm">JP</span>
                  <div tagx="suf">Jr</div>
               </li>
               <li tagx="au">
                  <span tagx="snm">LaMoreaux</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Werth</span>
                  <span tagx="fnm">JL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Poole</span>
                  <span tagx="fnm">RM</span>
               </li>
            </ul>
            <span tagx="source">Pain</span>
            <span tagx="pubdate">2001</span>
            <span tagx="volume">94</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">149</span>
            <span tagx="lpage">58</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0304-3959(01)00349-9</span>
                  <span tagx="pubid">11690728</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Minimal clinically important changes in chronic musculoskeletal pain intensity measured
                  on a numerical rating scale
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Salaffi</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stancati</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Silvestri</span>
                  <span tagx="fnm">CA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ciapetti</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grassi</span>
                  <span tagx="fnm">W</span>
               </li>
            </ul>
            <span tagx="source">Eur J Pain</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">8</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">283</span>
            <span tagx="lpage">91</span>
            <div tagx="note"> doi:10.1016/j.ejpain.2003.09.004</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.ejpain.2003.09.004</span>
                  <span tagx="pubid">15207508</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Alves da Cunha R, Fukuda VO, Rienzo FA, Cazarini Jr C, Carvalho Nde A, et al. Pulsed
                  shortwave treatment in women with knee osteoarthritis: a multicenter, randomized,
                  placebo-controlled clinical trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Fukuda</span>
                  <span tagx="fnm">TY</span>
               </li>
            </ul>
            <span tagx="source">Phys Ther</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">91</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">1009</span>
            <span tagx="lpage">17</span>
            <div tagx="note"> doi:10.2522/ptj.20100306</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.2522/ptj.20100306</span>
                  <span tagx="pubid">21642511</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Lateral wedge insoles for medial knee osteoarthritis: 12 month randomised controlled
                  trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bennell</span>
                  <span tagx="fnm">KL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bowles</span>
                  <span tagx="fnm">KA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Payne</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cicuttini</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Williamson</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Forbes</span>
                  <span tagx="fnm">A</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">342</span>
            <span tagx="fpage">d2912</span>
            <div tagx="note"> doi:10.1136/bmj.d2912</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.d2912</span>
                  <span tagx="pubid">21593096</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The role of internal pilot studies in increasing the efficiency of clinical trials</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wittes</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brittain</span>
                  <span tagx="fnm">E</span>
               </li>
            </ul>
            <span tagx="source">Stat Med</span>
            <span tagx="pubdate">1990</span>
            <span tagx="volume">9</span>
            <span tagx="issue">1–2</span>
            <span tagx="fpage">65</span>
            <span tagx="lpage">71</span>
            <div tagx="note"> discussion 71–2</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/sim.4780090113</span>
                  <span tagx="pubid">2345839</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="insg">
               <li tagx="ins">
                  <p>National Institute for Health and Care Excellence</p>
               </li>
            </ul>
            <span tagx="source">Guide to the methods of technology appraisal</span>
            <div tagx="publisher">NICE, London</div>
            <span tagx="pubdate">2008</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of a tailored activity pacing intervention on pain and fatigue for adults
                  with osteoarthritis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lyden</span>
                  <span tagx="fnm">AK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Smith</span>
                  <span tagx="fnm">DM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dong</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koliba</span>
                  <span tagx="fnm">JF</span>
               </li>
            </ul>
            <span tagx="source">Am J Occup Ther</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">64</span>
            <span tagx="issue">6</span>
            <span tagx="fpage">869</span>
            <span tagx="lpage">76</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.5014/ajot.2010.09198</span>
                  <span tagx="pubid">21218677</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The OARSI histopathology initiative - recommendations for histological assessments
                  of osteoarthritis in sheep and goats
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Little</span>
                  <span tagx="fnm">CB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Smith</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cake</span>
                  <span tagx="fnm">MA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Read</span>
                  <span tagx="fnm">RA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barry</span>
                  <span tagx="fnm">FP</span>
               </li>
            </ul>
            <span tagx="source">Osteoarthritis Cartilage</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">18</span>
            <span tagx="issue">Suppl 3</span>
            <span tagx="fpage">S80</span>
            <span tagx="lpage">92</span>
            <div tagx="note"> doi:10.1016/j.joca.2010.04.016</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.joca.2010.04.016</span>
                  <span tagx="pubid">20864026</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>One in four people may develop symptomatic hip osteoarthritis in his or her lifetime</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Helmick</span>
                  <span tagx="fnm">CG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schwartz</span>
                  <span tagx="fnm">TA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Renner</span>
                  <span tagx="fnm">JB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tudor</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koch</span>
                  <span tagx="fnm">GG</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Osteoarthritis Cartilage</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">18</span>
            <span tagx="issue">11</span>
            <span tagx="fpage">1372</span>
            <span tagx="lpage">9</span>
            <div tagx="note"> doi:10.1016/j.joca.2010.08.005</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.joca.2010.08.005</span>
                  <span tagx="pubid">20713163</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Mesenchymal stem cells and osteoarthritis: remedy or accomplice?</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Coleman</span>
                  <span tagx="fnm">CM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Curtin</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barry</span>
                  <span tagx="fnm">FP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">O’Flatharta</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">JM</span>
               </li>
            </ul>
            <span tagx="source">Hum Gene Ther</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">21</span>
            <span tagx="issue">10</span>
            <span tagx="fpage">1239</span>
            <span tagx="lpage">50</span>
            <div tagx="note"> doi:10.1089/hum.2010.138</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1089/hum.2010.138</span>
                  <span tagx="pubid">20649459</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>HIF-2alpha–a mediator of osteoarthritis?</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murphy</span>
                  <span tagx="fnm">CL</span>
               </li>
            </ul>
            <span tagx="source">Cell Res</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">20</span>
            <span tagx="issue">9</span>
            <span tagx="fpage">977</span>
            <span tagx="lpage">9</span>
            <div tagx="note"> doi:10.1038/cr.2010.99</div>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/cr.2010.99</span>
                  <span tagx="pubid">20625379</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The personal impact of osteoarthritis on individuals and how they use therapies: the
                  arthritis care OA Nation 2012 Survey
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Conaghan</span>
                  <span tagx="fnm">PG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Porcheret</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gammon</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Soni</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hurley</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rayman</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Ann Rheum Dis</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">71</span>
            <span tagx="issue">Suppl 3</span>
            <span tagx="fpage">584</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/annrheumdis-2012-eular.3278</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Abou-Raya A, Abou-Raya S, Khadrawe T. Methotrexate in the treatment of symptomatic
               knee osteoarthritis: randomised placebo-controlled trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204856.
            </div>
         </div>
      </div>
   </div>
</html>